Trial likes ORCHARD, SAVANNAH, TATTON showed savolitinib plus osimertinib could provide an ORR of 32%–67% in EGFR-TKI resistant NSCLC harboring MET upregulation including MET amplification and MET overexpression (Wu et al., 2024; Hartmaier et al., 2023). Here, EGFR is linked to non-small cell lung carcinoma.